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A B S T R A C T
The non-synonymous single nucleotide polymorphism (SNP), Val158Met within the Catechol-O-methyl-
transferase (COMT) gene has been associated with altered levels of cognition and memory performance in
cognitively normal adults. This study aimed to investigate the independent and interactional effects of COMT
Val158Met on cognitive performance. In particular, it was hypothesised that COMT Val158Met would modify
the effect of neocortical Aβ-amyloid (Aβ) accumulation and carriage of the apolipoprotein E (APOE) ε4 allele on
cognition in preclinical Alzheimer’s disease (AD). In 598 cognitively normal older adults with known neocortical
Aβ levels, linear mixed modelling revealed no significant independent or interactional associations between
COMT Val158Met and cognitive decline. These findings do not support previous associations between COMT
Val158Met and cognitive performance and suggest this variant does not influence Aβ-amyloid or APOE ε4 driven
cognitive decline in a well characterised cohort of cognitively normal older adults.
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1. Introduction
Catechol-O-methyltransferase (COMT) is an enzyme with an im-
portant role in the regulation of dopamine availability in the central
nervous system (CNS). The enzyme is encoded by the COMT gene
(Chromosome 22q11.21, (Grossman et al., 1992)) and allelic variation
in this gene plays an important role in enzymatic function. In particular,
the non-synonymous single nucleotide polymorphism (SNP) in exon 3,
rs4680 (NG_011526.1:g.27009G>A), results in a valine (Val) to me-
thionine (Met; Val158Met; henceforth referred to as COMT) substitu-
tion. Consequently, carriage of Met (COMTMet) confers a 3 to 4-fold
reduction in enzymatic activity resulting in higher levels of CNS do-
pamine, compared to carriage of Val (COMTVal) (Chen et al., 2004;
Lachman et al., 1996; Lotta et al., 1995).
Normal dopamine neurotransmission is essential for optimal human
cognition, mood and behaviour. Disruption to dopamine neuro-
transmission is associated with brain disease and mental illness.
Consequently, allelic variation in the COMT gene has been associated
with levels of cognition in cohorts of healthy individuals (Bellander
et al., 2015; Degen et al., 2016; Diamond et al., 2004; Dumontheil et al.,
2011; Egan et al., 2001; Goldberg et al., 2003; Malhotra et al., 2002;
Nagel et al., 2008; Rosa et al., 2004, 2010; Sheldrick et al., 2008; Starr
et al., 2007; Stefanis et al., 2005) and schizophrenia patients (Bilder
et al., 2002; Egan et al., 2001; Goldberg et al., 2003; Nolan et al., 2004;
Rosa et al., 2010), with carriage of COMTVal associated with poorer
performance. However, several studies and a meta-analysis (Barnett
et al., 2008) investigating healthy (Blanchard et al., 2011; de Frias
et al., 2010; Ho et al., 2005; Liu et al., 2014; O’Hara et al., 2006;
Papenberg et al., 2014; Potter et al., 2009; Stefanis et al., 2004; Stuart
et al., 2014; Wardle et al., 2013) and diseased individuals (e.g., with
schizophrenia (Dickerson et al., 2007; Ho et al., 2005; Zilles et al.,
2012), depression (Opmeer et al., 2013; Potter et al., 2009; Wang et al.,
2014), traumatic brain injury (Willmott et al., 2014), Parkinson’s dis-
ease (Hoogland et al., 2010), asymptomatic atherosclerosis (Bolton
et al., 2010)) have reported no association between COMT genotype
and cognitive performance. In particular, there is a general lack of
consensus with respect to the impact that COMT genotype has on
cognitive performance in healthy older adults, with studies finding a
positive influence of COMTMet (Bellander et al., 2015; Degen et al.,
2016; Nagel et al., 2008; Papenberg et al., 2014; Starr et al., 2007) or no
significant effect (de Frias et al., 2010; O’Hara et al., 2006; Stuart et al.,
2014). This inconsistency in results could, in part, be accounted for the
by variability in cognitive decline due to underlying pathogenic
changes occurring in the brain as a result of age related diseases.
In cohort studies of Alzheimer’s disease (AD), there is a lack of
consensus about the role played by COMT. A comprehensive meta-
analysis of 10 case-control studies revealed no significant associations
with AD risk either overall or in the Caucasian population, though as-
sociations were observed in the Asian population (Yan et al., 2016). An
increased risk for Mild Cognitive Impairment (MCI) and AD has pre-
viously been reported for COMTVal homozygotes, however, but only in
APOE ε4 carriers (Lanni et al., 2012). Whilst in a further study COMTVal
homozygotes were associated with conversion from cognitively normal
(unimpaired) status to MCI (Dixon et al., 2014). These latter studies
suggest that COMTVal homozygosity may be associated with early-stage
transition of cognitive phenotypes.
Cognitive changes are observable in the preclinical disease stages of
AD, which are characterised by high levels of neocortical Aβ-amyloid
(Aβ) (Lim et al., 2016). Additionally, this decline has been reported to
be modified by genetic factors including the Apolipoprotein E (APOE)
ε4 allele (Lim et al., 2013a, 2015) and the rs6265 and variants of the
Brain Derived Neurotropic Factor (BDNF) (Lim et al., 2013b) and
Kidney and Brian expressed protein (KIBRA) (Porter et al., 2018a)
genes, respectively. As such, genetic variation that has a differential
impact upon function may impart either susceptibility or resilience to
cognitive decline in the presence of the earliest stages of pathological
change, either independently or in combination. Interactional effects of
COMT and additional genetic factors have been previously investigated
in other disorders. However, there is a paucity of knowledge about the
impact of genetic variability in COMT on cognitive performance in
preclinical AD, particularly with respect to Aβ and APOE ε4 mediated
decline in cognitive domains that are impacted in the earliest stages of
the disease. Episodic memory is one of the earliest cognitive domains to
decline, with reductions in functioning reported to occur 4–8 years
prior to executive function and up to 7–10 years prior to other cognitive
domains (Derby et al., 2013; Elias et al., 2000; Grober et al., 2008).
The aim of this study was to investigate whether, in cognitively
normal (CN) older adults, allelic variation in COMT would be in-
dependently associated with cognitive decline, or modify Aβ or APOE-
ε4 mediated decline. The highly characterised Australian Imaging,
Biomarkers and Lifestyle (AIBL) Study of Aging provided 7.5 years of
cognitive and neuroimaging assessment data for longitudinal in-
vestigation. The hypothesis of the study was that in CN older adults,
carriage of the COMTVal allele (i.e COMTVal/Val or COMTVal/Met) would
be associated with poorer cognitive performance over time, as com-
pared to COMTMet homozygotes (i.e COMTMet/Met).
2. Methods
2.1. Participants
This study focused on imaged CN older adults (n= 598) enrolled in
the AIBL Study, a prospective longitudinal study of ageing launched in
2006. Additional information regarding the study design, enrolment
process, neuropsychological assessments, and exclusion and diagnostic
criteria has been previously described (Ellis et al., 2009). Each of the
AIBL Study member institutions (Austin Health, St Vincent’s Health,
Hollywood Private Hospital, and Edith Cowan University) granted
ethics approval for the study and informed written consent was pro-
vided by all volunteers.
2.2. Cognitive measures
At each 18-month data collection participants complete the AIBL
Study neuropsychological test battery, which includes the Mini-Mental
State Examination (MMSE), Clock Drawing Test, California Verbal
Learning Test-Second edition (CVLT-II), Logical Memory I and II (LMI;
LMII; Story A only), D-KEFS verbal fluency, a 30-item version of the
Boston Naming Test (BNT), Wechsler Test of Adult Reading (WTAR) for
premorbid IQ, Digit Span and Digit Symbol-Coding subtests of the
Wechsler Adult Intelligence Scale-Third edition (WAIS-III), the Stroop
task (Victoria version), and the Rey Complex Figure Test (RCFT) (Ellis
et al., 2009). Cognitive composite scores were calculated using the
neuropsychological test battery data in combination with the Clinical
Dementia Rating (CDR) as described previously (Burnham et al., 2015;
Donohue et al., 2014). Briefly, the cognitive composites investigated
herein included two measures of global cognition: a statistically driven
global cognition composite (CDRSB, MMSE, LMII, CVLTFP and Clock)
(Burnham et al., 2015), and the Pre-Alzheimer’s cognitive composite
(PACC (CVLT-II, LMII, MMSE, WAIS-III)) (Donohue et al., 2014), and a
measure of verbal episodic memory (CDR sum of boxes (CDRSB), LMII,
CVLT-II recognition false positives (CVLTFP) and long delay free recall
(CVLTLDFR)) (Burnham et al., 2015). The calculations of the statistically
driven global cognition and verbal episodic memory composites and
calculations included corrections for age, gender, years of education,
WTAR-estimated premorbid IQ (WAIS-III Full Scale Intelligence Quo-
tient (FSIQ)) and depressive symptoms (Geriatric Depression Scale
(GDS)) (Burnham et al., 2015).
2.3. Aβ-amyloid imaging
598 CN older adults underwent Aβ imaging with positron emission
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tomography (PET) using 11C-Pittsburgh Compound B (PiB), 18F-flor-
betapir or 18F-flutemetamol as previously described (Clark et al., 2011;
Rowe et al., 2010; Vandenberghe et al., 2010). PET standardized uptake
value ratios (SUVR) were determined for all tracers using CapAIBL, a
web-based freely available MR-less methodology (Bourgeat et al.,
2015). Briefly, SUVs were summed and normalized to either the cere-
bellar cortex SUV (PiB), whole cerebellum SUV (florbetapir) or pons
SUV (flutemetamol) to yield the target-region to reference-region
SUVR. These SUVRs were then classified as either low (Aβlow) or high
(Aβhigh) Aβ burden, based on a tracer-specific SUVR threshold: ≥1.4,
≥1.05 and ≥0.55 for PiB, florbetapir and flutemetamol, respectively
(Rowe et al., 2013).
2.4. Genotyping
Methods for DNA extraction and genotyping have been previously
described (Brown et al., 2014; Porter et al., 2018a, b). Briefly, QIAamp
DNA Blood Maxi Kits (Qiagen, Hilden, Germany) were used for DNA
extraction from whole blood as per manufacturer’s instructions.
TaqMan® genotyping assays (Life Technologies, Carlsbad, CA) for APOE
(rs7412, assay ID: C____904973_10; rs429358, assay ID:
C___3084793_20) and COMT (rs4680, assay ID: C__25746809_50) were
performed on a QuantStudio 12K Flex™ Real-Time-PCR systems (Ap-
plied Biosystems, Foster City, CA) using TaqMan® GTXpress™ Master
Mix (Life Technologies) following manufacturer’s instructions. APOE
status was defined by the presence (1 or 2 copies; APOE ε4+ve) or
absence (0 copies; APOE ε4-ve) of the APOE ε4 allele. Further, all
analyses were performed based on a dominant model for the COMT Val
allele (COMTVal= COMTVal/Val/COMTVal/Met; COMTMet= COMTMet/
Met).
2.5. Data analysis
All statistical analyses were performed using Rstudio (Rstudio
Team, 2015) Version 0.98.1103 for Macintosh (RStudio Team, 2015).
Baseline demographic data analyses provided means, counts, standard
deviations and percentages across the selected sample and stratified by
COMTVal and COMTMet status. Significant differences in demographic
measures between groups stratified by COMTVal and COMTMet status,
were assessed using Student’s t-tests for continuous variables (e.g. age,
premorbid IQ, depressive symptoms (GDS)) and chi-squared tests for
categorical variables (gender, years of education, APOE and Aβ burden
status).
Random intercepts linear mixed-effects (LME) models were per-
formed using the “nlme” package in R to assess differences in rates of
cognitive change relative to COMT. Initially, to investigate the effect of
COMT on the rate of cognitive decline, a COMT×Time interaction was
modelled across the entire sample, covarying for APOE ε4 carrier and
Aβ burden status, with the cognitive composites as the dependent
variables. Additionally, analyses in which the PACC is assessed age and
sex are included as covariates. The effect of Aβ status in combination
with COMT was then investigated by modelling an Aβ× COMT×Time
interaction, covarying for APOE ε4 carrier status. The final analysis
focused on low (Aβlow) and high Aβ (Aβhigh) participants separately, and
included APOE ε4 carrier status within the model by an
APOE× COMT×Time interaction. When nominally significant asso-
ciations were observed analyses were corrected for the False Discovery
Rate (FDR) using Q-Value (bootstrap method) (Storey, 2002).
3. Results
No significant differences were observed between either COMTMet
or COMTVal with respect to demographic variables with the exception of
depression (Table 1). As the mean depression values were well below
the clinically relevant threshold this result was not investigated further.
No associations between either COMTMet or COMTVal and differential
rates of decline were observed for any composite measures (Table 2).
COMT did not modify the impact of Aβ on cognition, with significant
differences only observed between Aβ groups in terms of rates of de-
cline (i.e. Aβlow/COMTMet and Aβlow/COMTVal significantly differed to
Aβhigh/COMTMet and Aβhigh/COMTVal; Table 3).
Further, COMT did not modify the effects of APOE in the Aβlow or
Aβhigh samples. In Aβlow (n= 340) no significant differences were ob-
served between any group’s rates of decline in any composites
(Table 4). Further, in Aβhigh (n= 258) significant differences in rates of
decline were only observed between APOE groups (i.e. APOE ε4-ve/
COMTMet and APOE ε4-ve/COMTVal significantly differed to APOE
ε4+ve /COMTMet and APOE ε4+ve /COMTVal; Table 4) in all compo-
sites. Similar results to those presented above were also observed when
investigating COMT using the dominant model for the Met allele
(COMTMet= COMTMet/Met/COMTVal/Met; COMTVal= COMTVal/Val) and
are presented in the Supplementary data (Tables A1–A4).
4. Discussion
The findings from this study do not support the initial hypothesis
that COMTVal carriers have significantly higher rates of cognitive de-
cline compared to COMTMet homozygotes. No significant modification
of cognitive decline by COMT was observed in any model investigated;
that is, independent of Aβ and APOE ε4 status COMT was not in-
dependently associated with cognitive decline in measures of global
cognition, verbal episodic memory, or the PACC. Further, COMT did not
modify Aβ-associated cognitive decline, nor was it observed to modify
the effect of APOE ε4 carrier status in individuals with high Aβ burden.
COMT has previously been associated with measures of cognition in
cognitively normal older adults (Bellander et al., 2015; Starr et al.,
2007), in particular episodic memory (Papenberg et al., 2014), working
memory (Nagel et al., 2008), and attention (Degen et al., 2016).
However, there have been a number of studies in cognitively normal
older adults that have reported no significant associations with mea-
sures of episodic memory (O’Hara et al., 2006; Stuart et al., 2014),
working memory (de Frias et al., 2010), verbal ability (O’Hara et al.,
2006), attention or speed of processing (O’Hara et al., 2006). As such,
the current study presented here is not unique in finding no significant
associations between COMT and cognitive performance. To the authors
knowledge this is the first study to investigate the modifying effects of
COMT on Aβ and APOE ε4 mediated cognitive decline in cognitively
normal older adults over a duration of 90 months.
The important role COMT has in regulating the availability of do-
pamine in the prefrontal cortex may contribute to the associations be-
tween COMT and cognitive tests that reflect changes in prefrontal
cortex function. However, similar to the current study several of the
aforementioned studies also failed to identify associations between
domains affected in preclinical AD and COMT. This current study fo-
cused primarily on cognitive composite scores that measure verbal
episodic memory, the cognitive domain affected earliest in AD (Derby
et al., 2013; Elias et al., 2000; Grober et al., 2008), or composites that
are statistically derived to reflect change in global cognition at the
earliest stages of the disease process. The lack of significant associations
observed could be due in part to the current study’s focus on preclinical
AD and specifically the cognitive domains impaired in these early
stages of preclinical AD. Further, episodic memory impairment is
known to result from damage to the medial temporal lobe, in particular
the hippocampus, rather than the prefrontal cortex, which is affected
later in AD and for which previous associations with COMT have been
reported.
Here we have thoroughly investigated the influence of COMT on
cognitive decline in cognitively normal older adults from a well char-
acterised longitudinal cohort of preclinical AD. The utilisation of
composite scores for cognitive domains that are impacted at the earliest
stages of AD is a strength of this study as it avoids the study of domains
that are likely to have a much smaller effect size and thus be
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significantly affected by sample size considerations. For example, Flint
et al. reported that considering the expected effect size of COMT on
working memory, a sample of 1700 participants would be required for a
significant association to be observed (Flint and Munafo, 2007). How-
ever, it is acknowledged that the study may be limited by the nature of
the recruitment of participants into the AIBL Study. AIBL Study parti-
cipants are not randomly selected and involvement is voluntary. Vo-
luntary involvement may have resulted in participants with higher le-
vels of education than would be expected from random community
recruitment, and this could have further hindered efforts to observe an
influence of COMT on cognitive decline.
5. Conclusion
Genetic variation has been suggested as a major contributing factor
to underpinning vulnerability or resilience to cognitive decline in the
presence of the earliest stages of pathological change in AD. This study
represents the first assessment of the influence of COMT on Aβ and
APOE ε4 mediated cognitive decline in a preclinical AD sample. The
results here suggest no independent or interactional influence, with
APOE or Aβ, of the COMT variant on measures of global cognition,
verbal episodic memory or the PACC. Whilst no independent effects
were observed it does not rule out the possibility that COMT may im-
part some influence on preclinical AD cognitive decline when combined
with other genetic factors.
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Table 1
Demographic Information.
Overall n= 598 COMTMet n= 139 COMTVal n=459 p
Age [years], mean (SD) 70.87 (6.45) 70.64 (6.39) 70.94 (6.47) 0.633
Female, n (%) 331 (55.35) 73 (52.52) 258 (56.21) 0.503
Years of Education, n (%) 0–8 46 (7.72) 13 (9.35) 33 (7.22) 0.435
9–12 218 (36.58) 45 (32.37) 173 (37.86)
13–15 124 (20.81) 34 (24.46) 90 (19.69)
15+ 208 (34.90) 47 (33.81) 161 (35.23)
Premorbid IQ [FSIQ] mean (SD) 108.00 (7.24) 108.42 (6.82) 107.87 (7.36) 0.434
Depressive Symptoms [GDS], mean (SD) 1.05 (1.32) 0.83 (1.06) 1.12 (1.32) 0.043
APOE ε4 carriage, n (%) 167 (27.93) 37 (26.62) 130 (28.32) 0.776
High Aβ burden, n (%) 258 (43.14) 55 (39.57) 203 (44.23) 0.382
Baseline demographic and clinical characteristics of all imaged cognitively normal adults in the AIBL Study, and stratified by COMT status (COMTVal and COMTMet).
p-values represent statistical significance when comparing COMT status. GDS, Geriatric Depression Scale; FSIQ, Wechsler Adult Intelligence Scale 3rd Edition (WAIS-
III) Full Scale Intelligence Quotient; SD, standard deviation.
Table 2
Mean slopes for cognitive composites in cognitively normal adults.
COMTMet n= 139 COMTVal n=459
β β p
Global 0.021 0.029 0.647
Verbal Episodic Memory 0.025 0.033 0.626
PACC −0.024 −0.017 0.875
Mean slopes for cognitive composites (presented in SD/year; n=598) in all
imaged cognitively normal participants, controlling for APOE ε4 carrier, Aβ
status and additionally age and sex in the PACC.
Table 3
Mean slopes for cognitive composites in cognitively normal adults, Aβ-amyloid interaction.
Aβlow/COMTMet n= 84 Aβlow/COMTVal n=256 Aβhigh/COMTMet n= 55 Aβhigh/COMTVal n=203
β β β β
Global 0.049 ϕ 0.050 ϕ −0.022 *^ −0.007 *^
Verbal Episodic Memory 0.054 ϕ 0.052 ϕ −0.019 *^ 0.002 *^
PACC 0.043 ϕ 0.049 ϕ −0.128 *^ −0.122 *^
Mean slopes for cognitive composites (presented in SD/year; n=598) in all imaged cognitively normal participants, controlling for APOE ε4 carrier and additionally
age and sex in the PACC. *p < 0.05 when comparing to the Aβlow/COMTMet group, ^p < 0.05 when comparing to the Aβlow/COMTVal group, ϕ p < 0.05 when
comparing to the Aβhigh/COMTMet group.
Table 4
Mean slopes for cognitive composites in cognitively normal adults stratified by
Aβ status, APOE ε4 interaction.
APOE ε4-ve
COMTMet
APOE ε4-ve
COMTVal
APOE ε4+ve
COMTMet
APOE ε4+ve
COMTVal
β β β β
Aβlow n=71 n=211 n=13 n=45
Global 0.053 0.051 0.031 0.050
Verbal Episodic
Memory
0.057 0.053 0.037 0.050
PACC 0.039 0.043 0.049 0.070
Aβhigh n=31 n=118 n=24 n=85
Global 0.028 ϕ 0.024 ϕ −0.105 *^ −0.059 *^
Verbal Episodic
Memory
0.028 ϕ 0.029 ϕ −0.094 *^ −0.044 *^
PACC 0.134 ϕ 0.107 ϕ −0.227 *^ −0.142 *^
Mean slopes for cognitive composites (presented in SD/year) in cognitively
normal participants with low Aβ-amyloid burden (Aβlow; n= 340) or high Aβ-
amyloid burden (Aβhigh; n= 258), controlling for age and sex in the PACC
analysis. *p < 0.05 when comparing to the APOE ε4-ve COMTMet group,
^p < 0.05 when comparing to the APOE ε4-ve COMTVal group, ϕ p < 0.05
when comparing to the APOE ε4+ve COMTMet group.
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